Retatrutide Is Not Compoundable

The short answer is no: retatrutide is not compoundable in the United States. FDA says retatrutide "cannot be used in compounding under federal law" and adds that it is not a component of an FDA-approved drug and has not been found safe and effective for any condition.^[1]

That is a stronger statement than "not available yet." It means a pharmacy cannot make a patient prescription for retatrutide just because a prescriber writes one, and a website selling "research retatrutide" is not the same thing as a legitimate trial or pharmacy supply chain.

Why retatrutide is not compoundable

Compounding law is narrower than many peptide forums make it sound. FDA's bulk-substance framework separates traditional 503A pharmacies from 503B outsourcing facilities, but both pathways have limits.^[2]

For a 503A pharmacy, a bulk drug substance generally must fit one of these pathways:

• It complies with an applicable USP or National Formulary monograph.
• It is a component of an FDA-approved drug product when no monograph exists.
• It appears on FDA's 503A bulks list.

For a 503B outsourcing facility, the substance generally must either appear on FDA's 503B clinical-need bulks list or be used to compound a drug product that appears on FDA's drug shortage list at the time of compounding, distribution, and dispensing.^[2]

Retatrutide does not fit those routes. FDA's GLP-1 safety page states the practical result plainly: retatrutide cannot be used in compounding under federal law.^[1]

Why this differs from semaglutide and tirzepatide

Semaglutide and tirzepatide are FDA-approved active ingredients in marketed drugs. Their compounding disputes have centered on shortage status, patient-specific need, bulk-substance policy, and copies of commercially available drugs.

Retatrutide is different. It is still investigational. There is no FDA-approved retatrutide drug product, no retail prescription version, and no lawful shortage-based copy of an approved retatrutide product. That is why "my clinic can prescribe compounded retatrutide" is a red flag rather than a normal access pathway.

Trial-only access

Retatrutide is being studied in Eli Lilly's Phase 3 program under the development code LY3437943. ClinicalTrials.gov lists retatrutide studies in obesity, overweight, type 2 diabetes, chronic low back pain, osteoarthritis, obstructive sleep apnea, and related cardiometabolic indications.^[4][5][6]

Clinical trial access is not the same as shopping for a medication. A trial has eligibility criteria, informed consent, protocol visits, monitoring, randomization, and a sponsor-controlled investigational supply. Some participants may receive placebo. Some sites may be active but not recruiting, and some trials may have no nearby location.

If someone wants legitimate retatrutide access today, the practical path is to search ClinicalTrials.gov for "retatrutide" or "LY3437943" and contact listed study sites. A clinic, spa, or online vendor offering immediate paid access is not offering the same thing.

Why "research" vendors are not equivalent

The "research use only" label can make a product look official, but it does not turn an unapproved vial into a medication.

FDA has warned companies that sold unapproved GLP-1 products containing semaglutide, tirzepatide, or retatrutide while labeling them "for research purposes" or "not for human consumption." FDA says these products have been sold directly to consumers for human use with dosing instructions, are of unknown quality, and may be harmful.^[1]

That matters because research vendors are not equivalent to any of these:

• FDA-approved manufacturers: no approved retatrutide product exists.
• Licensed compounding pharmacies: retatrutide cannot be used in compounding under federal law.
• Clinical trial supply: trial drug is controlled under a protocol with sponsor oversight, monitoring, and reporting.
• Generic drugs: generics require FDA approval and therapeutic-equivalence review; retatrutide has neither.

FDA also emphasizes that even lawful compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.^[3] Research-use vendor products sit outside even that pharmacy framework.

If a provider offers "compounded retatrutide"

Treat the offer as a regulatory warning sign. Useful questions are:

• Is the product being dispensed by a state-licensed pharmacy or FDA-registered 503B outsourcing facility?
• What is the legal basis for compounding a substance FDA says cannot be used in compounding?
• Is the product labeled as a patient prescription, an office-use product, or "research use only"?
• Is the provider claiming FDA approval, generic equivalence, or pharmacy compounding status?

If the answer depends on "research use only," "not for human consumption," "not technically a prescription," or "the law is a gray area," that is not the same as legal retatrutide access.

FAQ

Is retatrutide compoundable?

No. FDA states that retatrutide cannot be used in compounding under federal law.^[1]

Can a 503A or 503B pharmacy make retatrutide?

FDA's current public position is no. The general 503A and 503B bulk-substance pathways are limited, and FDA specifically identifies retatrutide as a GLP-1 drug that cannot be used in compounding.^[1][2]

Can I buy retatrutide for research?

You may see vendors advertising it, but that is not equivalent to a medication, prescription, compounded product, or clinical trial supply. FDA has warned about unapproved GLP-1 products sold under "research purposes" or "not for human consumption" labels.^[1]

When will retatrutide be available?

Unknown. Retatrutide is still investigational. Approval would require successful clinical trials, an FDA submission, and FDA review. Until then, legitimate access is through clinical trial enrollment.

---

---

Related content

Peptide

Retatrutide Profile

Full evidence profile covering retatrutide's mechanism, Phase 2 and Phase 3 data, safety signals, and regulatory status.

News

Semaglutide Compounding Under Scrutiny

The GLP-1 compounding context around shortages, FDA scrutiny, and legal risk.

News

What Are Compounding Pharmacies?

How 503A and 503B compounding frameworks work, and why pharmacy access is different from gray-market supply.

---

References

1. [1]

   U.S. Food and Drug Administration. “FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” 2026. LinkSafety study

   FDA safety communication. States retatrutide cannot be used in compounding under federal law and warns about GLP-1 products falsely labeled for research purposes or not for human consumption.

2. [2]

   U.S. Food and Drug Administration. “Bulk Drug Substances Used in Compounding.” 2026. Link

   FDA explanation of the 503A and 503B limits on which bulk drug substances may be used in human drug compounding.

3. [3]

   U.S. Food and Drug Administration. “Understanding the Risks of Compounded Drugs.” 2026. LinkSafety study

   FDA consumer and professional information explaining that compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.

4. [4]

   ClinicalTrials.gov. “NCT05929066: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight.” 2026. LinkRCT

   Official U.S. clinical trial registry record for a Phase 3 retatrutide obesity/overweight study sponsored by Eli Lilly.

5. [5]

   ClinicalTrials.gov. “NCT07035093: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain.” 2026. LinkRCT

   Official U.S. clinical trial registry record for a recruiting Phase 3 retatrutide study in obesity/overweight with chronic low back pain.

6. [6]

   ClinicalTrials.gov. “NCT07232719: A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight.” 2026. LinkRCT

   Official U.S. clinical trial registry record for a recruiting Phase 3b retatrutide study in obesity/overweight.